Management of transformed SCLC from EGFR-mutated lung adenocarcinoma is based on use of chemotherapy including etoposide/carboplatin and taxanes, which results in a median OS of 10.9 months [93]. This evidence concerns the gene EGFR and lung adenocarcinoma.